Skip to main content
SpringerLink
Log in

Therapie der Hepatitis C Virusinfektion

  • Published:
Wiener klinische Wochenschrift Education

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.

    Article  CAS  PubMed  Google Scholar 

  2. Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–33.

    Article  CAS  PubMed  Google Scholar 

  3. Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–91.

    Article  PubMed  Google Scholar 

  4. Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–4.

    Article  PubMed  Google Scholar 

  5. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: a high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.

    Article  PubMed  Google Scholar 

  6. Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C-virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.

    Article  CAS  PubMed  Google Scholar 

  7. Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999;354:2119–24.

    Article  CAS  PubMed  Google Scholar 

  8. Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78–85.

    Article  CAS  PubMed  Google Scholar 

  10. Beinhardt S, Payer BA, Datz C, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59:972–7.

    Article  PubMed  Google Scholar 

  11. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20 year multicenter study. Hepatology. 2000;32:91–6.

    Article  CAS  PubMed  Google Scholar 

  12. Nomura H, Tanimoto H, Nagahama T, et al. Short-term interferon-alfa therapy for acute hepatitis C. Hepatology. 2004;39:1213–9.

    Article  CAS  PubMed  Google Scholar 

  13. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2014. pii: gutjnl-2014-306997. doi:10.1136/gutjnl-2014-306997.

  14. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344–50.

    Article  PubMed  Google Scholar 

  15. Licata A, DiBona D, Schepis F, et al. When and how to treat acute hepatitis C. J Hepatol. 2003;39:1056–62.

    Article  CAS  PubMed  Google Scholar 

  16. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.

    Article  CAS  PubMed  Google Scholar 

  17. Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:521–31.

    Article  CAS  PubMed  Google Scholar 

  18. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. doi:10.1001/jama.2012.144878.

    Article  PubMed  Google Scholar 

  19. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QEST-1, a phase III trial. Lancet. 2014;384:403–13.

    Article  CAS  PubMed  Google Scholar 

  20. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet. 2014;384:414–26.

    Article  CAS  PubMed  Google Scholar 

  21. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic Hepatitis C infection. N Engl J Med. 2013;368:1878–87.

    Article  CAS  PubMed  Google Scholar 

  22. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65. doi:10.1016/S0140–6736(14)61036–9. (Epub 2014 Jul 28).

    Article  CAS  PubMed  Google Scholar 

  23. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.

    Article  PubMed  Google Scholar 

  24. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.

    Article  CAS  PubMed  Google Scholar 

  25. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.

    Article  PubMed  Google Scholar 

  26. Bourliere M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014;60(Suppl 1):239A.

    Google Scholar 

  27. Bourliere M, et al. Sofosbuvir/Ledipasvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed to protease inhibitor based triple therapy. Hepatology. 2014;60:1270A.

    Google Scholar 

  28. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.

    Article  PubMed  Google Scholar 

  29. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65.

    Article  CAS  PubMed  Google Scholar 

  30. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.

    Article  PubMed  Google Scholar 

  31. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.

    Article  CAS  PubMed  Google Scholar 

  32. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.

    Article  CAS  PubMed  Google Scholar 

  33. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.

    Article  CAS  PubMed  Google Scholar 

  34. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.

    Article  PubMed  Google Scholar 

  35. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015. doi:10.1002/hep.27726.

  36. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014;60:1275A.

    Google Scholar 

  37. Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129–30A.

    Google Scholar 

  38. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014;60(Suppl 1):321A.

    Google Scholar 

  39. Beinhardt S, Peck-Radosavjevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of liver transplant patients with chronic hepatitis C. Transpl Int. 2015. doi:10.1111/tri.12577.

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Währingergürtel 18–20, 1090, Wien, Österreich

    Clarissa Freissmuth, Peter Ferenci &  Harald Hofer

Authors
  1. Clarissa Freissmuth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Ferenci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Harald Hofer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harald Hofer.

Fragen

Fragen

In ungefähr welchem Prozentsatz kommt es bei Neuinfektionen/akuter Hepatitis C zu einer Chronifizierung der HCV Infektion? (1 richtige Antwort)

3–5 %

20–30 %

70–85 %

95–100 %

Welches klinische Symptom ist ein günstiges Zeichen für den Spontanverlauf der akuten Hepatitis C? (1 richtige Antwort)

Aszites

Ikterus

Enzephalopathie

Juckreiz

Über welchen Zeitraum ist per definitionem der Nachweis des Hepatitis C Virus notwendig, um die Diagnose einer chronischen Hepatitis C stellen zu können? (1 richtige Antwort)

3 Monate

3 Jahre

6 Monate

12 Monate

Welcher Virusgenotyp zeigt in Österreich die höchste Prävalenz? (1 richtige Antwort)

HCV Genotyp 1

HCV Genotyp 2

HCV Genotyp 3

HCV Genotyp 4

Welche Merkmale stellen ungünstige Vorraussetzungen hinischtlich Heilungschancen für eine Interferon-freie Therapie mit Sofosbuvir/Ribavirin bei HCV Genotyp 3 dar. (2 richtige Antwort)

Vorhandensein einer Leberzirrhose

Erfolglose Vortherapie mit Interferon/Ribavirin

Niedrige Viruslast

Niedriger Body Mass Index

Welche der folgenden Symptome/Diagnosen stellen Langzeitkomplikationen bzw. Spätfolgen der chronischen Hepatitis C dar. (3 richtige Antworten)

Hepatozelluläres Karzinom

Portale Hypertension

Hepatische Enzephalopathie

Hohe Viruslast

Wie sind die gegenwärtigen Therapieempfehlungen hinsichtlich der Therapiedauer mit Sofosbuvir/Ribavirin bei HCV Genotyp 2 Patienten (1 richtige Antwort)

Sofosbuvir/Ribavirin über 12 Monate

Sofosbuvir/Ribavirin über 12 Wochen

Sofosbuvir/Ribavirin über 6 Monate

Sofosbuvir/Ribavirin über 6 Wochen

Wie lange ist die Therapiedauer mit Sofosbuvir/Ribavirin bei HCV Genotyp 3 Patienten (1 richtige Antwort)

Sofosbuvir/Ribavirin über 12 Monate

Sofosbuvir/Ribavirin über 12 Wochen

Sofosbuvir/Ribavirin über 6 Monate

Sofosbuvir/Ribavirin über 6 Wochen

Welche Nebenwirkungen sind häufig unter einer Interferon-basierten antiviralen Therapie (3 richtige Antworten)

Blutbildveränderungen

Depressionen

Grippe-artige Symptome (Fieber, Kopfschmerzen, Gliederschmerzen)

Tremor

Zu welcher Gruppe der direkt antiviral wirksamen Substanzen zählt Dasabuvir? (1 richtige Antwort)

Proteasehemmer

Interferon

NS5A-Inhibitor

Polymerasehemmer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freissmuth, C., Ferenci, P. & Hofer, H. Therapie der Hepatitis C Virusinfektion. Wien. Klin. Wochenschr. Educ 10, 61–72 (2015). https://doi.org/10.1007/s11812-015-0072-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11812-015-0072-7

Search

Navigation